1279692-10-2

Upstream product

• 942045-32-1 6-chloro-N-(4-fluorophenyl)-6-morpholino-1,3,5-triazin-2-amine 
• 330569-41-0 (4-fluorophenyl)-(4-hydrazino-6-morpholin-4-yl-[1,3,5]triazin-2-yl)amine 
• 66-99-9 β-naphthaldehyde 
• 6601-22-5 2,6-Dichloro-4-morpholino-1,3,5-triazine 
• 371-40-4 4-fluoroaniline 
• 131468-33-2 (4,6-dichloro-[1,3,5]triazin-2-yl)-(4-fluorophenyl)-amine 

Relevant academic research and scientific papers

Toward the Discovery of Novel Anti-HIV Drugs. Second-Generation Inhibitors of the Cellular ATPase DDX3 with Improved Anti-HIV Activity: Synthesis, Structure-Activity Relationship Analysis, Cytotoxicity Studies, and Target Validation

A hit optimization protocol applied to the first nonnucleoside inhibitor of the ATPase activity of human DEAD-box RNA helicase DDX3 led to the design and synthesis of second-generation rhodanine derivatives with better inhibitory activity toward cellular DDX3 and HIV-1 replication. Additional DDX3 inhibitors were identified among triazine compounds. Biological data were rationalized in terms of structure-activity relationships and docking simulations. Antiviral activity and cytotoxicity of selected DDX3 inhibitors are reported and discussed. A thorough analysis confirmed human DDX3 as a valid anti-HIV target. The compounds described herein represent a significant advance in the pursuit of novel drugs that target HIV-1 host cofactors.

COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF

The present invention relates to the medical use of the compound of formula 1,2,3 or 4